Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Protalix Biotherapeutics Inc    

PROTALIX BIOTHERAPEUTICS INC

  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 3,91x
Capi. / Sales2014 1,72x
Capitalization 61,7 M
More Financials
Company
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
03/19PROTALIX BIOTHERAPEUTICS : Reports 2018 Full Year Results and Provides Corporate..
AQ
03/18PROTALIX BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Con..
AQ
03/18PROTALIX BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Con..
AQ
03/18PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, ..
AQ
03/18Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporat..
GL
03/13Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate..
GL
03/07PROTALIX BIOTHERAPEUTICS : to Hold Full-Year 2018 Financial Results and Corporat..
AQ
03/06PROTALIX BIOTHERAPEUTICS : to Hold Full-Year 2018 Financial Results and Corporat..
AQ
02/06PROTALIX BIOTHERAPEUTICS : Presents Preliminary Data from the BRIGHT Study of pe..
AQ
02/05PROTALIX BIOTHERAPEUTICS, INC. : Other Events (form 8-K)
AQ
More news
Analyst Recommendations on PROTALIX BIOTHERAPEUTICS I
More recommendations
Sector news : Biotechnology & Medical Research - NEC
04/16GILEAD SCIENCES : Insitro to Collaborate on Nonalcoholic Steatohepatitis
DJ
04/15PATRICK THOMAS : Novartis Files Application for Macular Degeneration Treatment
DJ
04/12GILEAD SCIENCES : Novo Nordisk Plan NASH Collaboration
DJ
04/08GSK wins U.S. nod for two-drug HIV combination
RE
04/08Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart PROTALIX BIOTHERAPEUTICS INC
Duration : Period :
Protalix Biotherapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 1 456%
EPS Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Yaron Naos Senior Vice President-Operations
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTICS INC39.95%62
IQVIA HOLDINGS INC14.50%26 285
CELLTRION, INC.--.--%24 574
LONZA GROUP16.76%21 828
INCYTE CORPORATION16.31%15 847
EXACT SCIENCES CORPORATION46.13%11 596